The NIH Center for Regenerative Medicine

Embryonic Stem Cell (ESC)/Induced Pluripotent Stem Cells (iPSC)

iPSC Reprogramming From Human Peripheral Blood Using Sendai Virus Mediated Gene Transfer

View PDF version

Title

iPSC Reprogramming From Human Peripheral Blood Using Sendai Virus Mediated Gene Transfer

Date Submitted

April 26, 2012

Submitted by -

Yang, Wenli

Adapted from -

UPenn iPSC Core and CHOP iPSC Core in-house protocols

Contributors -

1Yang, Wenli; 1Liu, Ying; 2Sullivan, Spencer; 2Mills, Jason

Affiliation(s) -

1University of Pennsylvania, 2Children’s Hospital of Philadelphia

Introduction:

This protocol allows efficient generation of integration-free iPS cells from a small amount of peripheral blood (less than 1 ml).   Peripheral blood mononuclear cells (PBMCs) are briefly cultured to expand the erythroblast (EB) population.  They are then used to derive iPS cells using four recombinant Sendai viral vectors, expressing the four reprogramming factors Oct4, Sox2, Kfl4 and c-Myc.

Flowchart:

iPSC Reprogramming From Human Peripheral Blood Using Sendai Virus Mediated Gene Transfer

Materials and Preparation:

Reagents Supplier Catalogue number

QBSF-60

Quality Biologicals

160-204-101

Primocin

Invivogen

ant-pm-1

Pen/Strep

Life Technologies

15140-155

DMEM (high glucose)

Life Technologies

11965-118

Non-Essential Amino Acid (MEM-NEAA)

Life Technologies

11140-050

L-Glutamine

Life Technologies

25030-156

CytotuneTM- iPS Sendai Reprogramming kit 

 

A1378001

DMEM/F12

Life Technologies

11330

2-Mercaptoetheranol

Sigma

M7522 -100ml

b-FGF

Life Technologies

PHG0021

Knockout Serum Replacement (KOSR)

Life Technologies

10828

FBS

Life Technologies

16000-044

Define FBS

Hyclone

SH30070.01

MEF feeders

Global Stem

6001G

0.1% geletin

Millipore

ES-006-B

Recombinant human EPO (tissue culture grade)

R&D Systems

287-TC-500

Recombinant human IL-3, CF

R&D Systems

203-IL-010/CF

Recombinant human IGF-1, CF

R&D Systems

291-G1-200

Recombinant human SCF, CF

R&D Systems

255-SC-010/CF

Dexamethasone

Sigma

D8893-1MG

L-Ascorbic Acid

Sigma

A4544-25G

Expansion Medium (EM)* Stock conc

Final Conc

Volume

QBSF-60 (serum free medium)

 

 

10 mL

(Antibiotics)

 

 

 

Primocin

500x

100 µg /mL

20 µL

Pen/Strep

100x

1%

100 µL

Ascorbic Acid (AA)

10 mg/mL

50µg /mL

50 µL

(Growth factors)

 

 

 

SCF

50 µg/mL

50 ng/mL

10 µL

IL-3

10 µg/mL

10 ng/mL

10 µL

EPO

2 U/µL

2 U/mL

10 µL

IGF-1

100 µg/mL

40 ng/mL

4 µL

Dexamethasone**

1mM

1µM

10 µL

*EM = QBSF (base media) + AA + growth factors
EM+P/S = QBSF (base media) + P/S + AA + growth factors
EM+Primocin = QBSF + primocin + AA + growth factors
**Keep dexamethasone and doxycycline protected from light (discard every 2 weeks)

MEF media (500 ml)
DMEM (high glucose): 450 ml                                                                 
FBS: 50 ml                         
NEAA: 5 ml
L-glutamine                                      
Pen/Strep: 5 ml                                              

iPSC Media (500 ml)
DMEM/F12: 450 ml
Define FBS:  50 ml
NEAA: 5 ml
L-glutamine: 5ml
Pen/strep: 5 ml
2-mercaptoethonol: 3.5 µl
b-FGF: 10 ng/ml (50 µl of 100 µg/ml stock)
L-Ascorbic Acid: 50 µg/ml –add fresh 10mg/ml stock at each media change 

hES Media (500 ml)
DMEM/F12: 400 ml
KOSR: 100 ml
NEAA: 5 ml
L-glutamine: 5ml
Pen/strep: 5 ml
2-mercaptoethonol: 3.5 µl
b-FGF: 10 ng/ml (50 µl of 100 ug/ml stock)
L-Ascorbic Acid: 50 µg/ml –add fresh 10mg/ml stock at each media change

Protocol

D -9 to -12
Collect blood into BD Vacutainer 4 or 8 mL cell preparation tube (CPT) with sodium citrate1 or into EDTA or heparinized tubes and Ficoll extract PBMCs.  Alternatively, thaw frozen PBMCs.

Fresh cells collected into CPT (8 ml)

  1. Draw 8 mL of PB into CPT. Invert tube 8-10x and keep upright at room temperature (RT)
  2. Centrifuge 30 min at 1,800 RCF at RT (ideally within 2 hrs of collection)
  3. Use a sterile transfer pipette to collect buffy coat into sterile 15 mL conical centrifuge tube
  4. Bring total volume to 10 mL with sterile 1x PBS, invert several times
  5. Centrifuge 15 minutes at 300 RCF and aspirate supernatant                       
  6. Resuspend pellet in 10 mL of sterile 1x PBS and perform cell count (The yield should be ~1-2x106 cells/ml of PB)
  7. Transfer 1 to 2x106 cells into sterile 15 mL conical centrifuge tube and centrifuge at 300 RCF for 10 min
  8. Resuspend pellet in 2 mL of expansion medium (EM) + primocin and transfer to 1 well of a 12 well dish
  9. Incubate cells at 37C
  10. Centrifuge remaining cells at 300 RCF for 10 min and freeze 1 to 2x106 cells/vial (Use 90% serum, 10% DMSO for freezing medium). 

Frozen cells

  1. Thaw 1 vial of PBMCs into 10 mL of QBSF and centrifuge at 300 RCF for 10 min
  2. Resuspend pellet in 2 mL of EM + primocin and transfer to 1 well of a 12 well dish, incubate at 37C

D-6 and D-3 (Pre-Transduction)

Switch media to EM (no antibiotics) at D-6 and collect spent media at D-3 for mycoplasma testing.  Continue to culture in EM+P/S from D-3 on.

  1. Transfer cells to sterile 15 mL conical tube and wash well 1x with 1 mL of QBSF to collect adherent cells
  2. Spin cells at 300 RCF for 10 min and resuspend in 2 mL of fresh EM
  3. Continue to culture in 1 well of a 12 well dish

D-2 to D0 (FACS for Erythroblast markers)

  1. EM media expands the erythroblast population from PBMCs.  A 2-fold expansion should occur in about 9-12 days with an initial decrease in cell number.  When cells are noticeably dividing and have reached the appropriate density, perform FACS to monitor erythroblast expansion using antibodies to erythroblast cell surface markers (see support protocol).  When more than 90% of the cells express CD36 and CD71, you can proceed to transduction.  

D0 (Transduction)
4 Sendai viruses (CytoTuneTM) each expressing Oct3/4, Sox2, Klf4, c-Myc are used for transduction. We have found that 2.5x105 cells and 10 MOI of each virus gives >1% reprogramming efficiency.  So less cells and/or lower MOI may be sufficient to generate enough colonies for picking.

  1. Transfer cells to sterile 15 mL conical tube and wash well 1x with 1 mL of QBSF to collect adherent cells
  2. Count cells
  3. Spin down 2.5x105 cells in 15 mL conical tube and add 1 mL of fresh EM+P/S plus viruses and transfer to one well of a 12 well plate.
  4. Spinnoculation: Spin plate at 2250 rpm at 25C x 90 min. 
  5. While spinning, divide the remaining cells into two tubes and spin down.  Save one tube for RNA and one for DNA.
  6. After spin, move plate to incubator with 5% O2 and culture at this condition from now on
  7. At end of day, add an additional 1 mL of fresh EM+P/S to cells (for a total of 2 ml of EM+P/S)

D1 (Wash virus)

  1. Collect and spin cells at 300 RCF in a conical tube for 10 min and resuspend in 2 mL of fresh EM+P/S

D2 Plate MEFs

  1. Plate MEFs onto 0.1% Gelatin coated 6-well TC plates

D3 (Plate transduced cells)

  1. Collect cells into 15 mL conical tube and spin at 300 RCF for 10 min.
  2. Resuspend cells in 6 mL of iPSC media plus growth factors as above
  3. Plate 1 mL/well into 6 well MEF plate.  Add additional 1.5 mL/well of iPSC media plus growth factors for a total of 2.5 mL of media/well
  4. Spin plate at 500 rpm at 25C x 30 min

D5…

  1. Feed cells every other day with 2.5 mL of iPSC media.
  2. Aspirate and discard floating cells with each feed, add additional MEFs as needed (~1x/wk)

~D9-12 (Small colonies emerge)

  1. Once small colonies appear, feed cells daily with 2 mL of hES media.
  2. Add additional MEFs as needed (~1x/wk)

~D14-21 (Pick colonies)

  1. Each colony is picked into one well of a 12-well or 24-well plate with MEFs on gelatin with 1 mL/well of hES media plus 10mM Rock inhibitor.
  2. Feed cells two days later and then daily thereafter with 1 mL of hES media.  Continue to expand clones for characterization.

    Time course of iPSC generation

Caption:  Time course of iPSC generation

Support protocol:  FACS analysis of erythroblast surface markers expression

Materials and Preparation

Reagents Supplier Catalog Number
PE mouse IgG2a isotype control BD 555575
FITC mouse IgM isotype control BD 555584
PE mouse anti-human CD71 BD 561938
FITC mouse anti-human CD36 BD 561820
PBS Life Technologies 14190-136
Round bottom FACS tubes BD 352054
DMEM/F12 Life Technologies 11330
2-Mercaptoetheranol Sigma M7522 -100ml

Staining Buffer: 10% FBS in PBS

Protocol

  1. Harvest cells from the 12-well plate in a 15 ml conical tube
  2. Centrifuge for 10 min at 400 RCF
  3. Discard the supernatant and resuspend cells in 1mL EM media
  4. Count cells and transfer 100,000 cells to round bottom tubes with 3 ml of ice-cold PBS
  5. Centrifuge cells for 5 min at 400 RCF
  6. Discard the PBS and resuspend cells with 100 µL staining buffer.
  7. Stain cells with 1µL of each of the antibodies (isotype controls, CD36, CD71, CD36+CD71) at 4°C for 30 min
  8. Wash cells with 3 ml ice-cold PBS and centrifuge for 10 min at 0.4 RCF; repeat wash
  9. Discard the supernatant by inverting the tube and fix cells with 200 L 1% paraformaldehyde.  Proceed with flow cytometry acquisition.

    Surface expression of two erythroblast markers CD36 and CD71.  90% of the cells should be positive for these markers before they can be used for reprogramming.

Caption:  Surface expression of two erythroblast markers CD36 and CD71.  90% of the cells should be positive for these markers before they can be used for reprogramming.

References

  1. REF #362760 (http://www.bd.com/vacutainer/pdfs/bd_cpt_VDP40104.pdf)
  2. Chou et al. 2011. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.  Cell Research
  3. Van den Akker et al. 2010. The majority of the in vitro erythroid expansion potential resides in CD34(-) cells, outweighing the contribution of CD34(+) cells and significantly increasing the erythroblast yield from peripheral blood samples.  Haematologica
  4. Leberbauer et al. 2005. Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors.  Blood

This page was last modified on October 18, 2012